Gilead Sciences Gross Profit 2010-2022 | GILD

Gilead Sciences annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Gilead Sciences gross profit for the quarter ending September 30, 2022 was $5.647B, a 8.89% decline year-over-year.
  • Gilead Sciences gross profit for the twelve months ending September 30, 2022 was $20.248B, a 8.42% decline year-over-year.
  • Gilead Sciences annual gross profit for 2021 was $20.704B, a 2.92% increase from 2020.
  • Gilead Sciences annual gross profit for 2020 was $20.117B, a 13.18% increase from 2019.
  • Gilead Sciences annual gross profit for 2019 was $17.774B, a 2.89% increase from 2018.
Gilead Sciences Annual Gross Profit
(Millions of US $)
2021 $20,704
2020 $20,117
2019 $17,774
2018 $17,274
2017 $21,736
2016 $26,129
2015 $28,633
2014 $21,102
2013 $8,343
2012 $7,231
2011 $6,261
2010 $6,080
2009 $5,416
Gilead Sciences Quarterly Gross Profit
(Millions of US $)
2022-09-30 $5,647
2022-06-30 $4,818
2022-03-31 $5,166
2021-12-31 $4,617
2021-09-30 $6,198
2021-06-30 $4,827
2021-03-31 $5,062
2020-12-31 $6,023
2020-09-30 $5,436
2020-06-30 $4,079
2020-03-31 $4,579
2019-12-31 $4,196
2019-09-30 $4,569
2019-06-30 $4,685
2019-03-31 $4,324
2018-12-31 $4,225
2018-09-30 $4,510
2018-06-30 $4,452
2018-03-31 $4,087
2017-12-31 $4,693
2017-09-30 $5,480
2017-06-30 $6,015
2017-03-31 $5,548
2016-12-31 $6,245
2016-09-30 $6,371
2016-06-30 $6,912
2016-03-31 $6,601
2015-12-31 $7,444
2015-09-30 $7,231
2015-06-30 $7,246
2015-03-31 $6,712
2014-12-31 $6,251
2014-09-30 $5,055
2014-06-30 $5,610
2014-03-31 $4,186
2013-12-31 $2,262
2013-09-30 $2,101
2013-06-30 $2,083
2013-03-31 $1,897
2012-12-31 $1,912
2012-09-30 $1,829
2012-06-30 $1,788
2012-03-31 $1,702
2011-12-31 $1,616
2011-09-30 $1,590
2011-06-30 $1,603
2011-03-31 $1,452
2010-12-31 $1,502
2010-09-30 $1,460
2010-06-30 $1,472
2010-03-31 $1,645
2009-12-31 $1,559
2009-09-30 $1,392
2009-06-30 $1,264
2009-03-31 $1,201
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $104.541B $27.305B
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00